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Late initiation of HIV antiretroviral therapy in pregnancy is associated with failure to achieve viral 
suppression by delivery and increased infant transmission of HIV. We evaluated virological 




DolPHIN-2 (NCT03249181) randomized pregnant women in South Africa and Uganda initiating 
antiretroviral therapy in third trimester between January-August 2018 1:1 to open-label dolutegravir 
vs efavirenz-based therapy. Viral load was measured serially to delivery visit (0-14 days post-
partum). We report the primary efficacy outcome (viral load<50 copies per mL at delivery visit), and 
the primary safety outcome (occurrence of drug-related adverse events in mothers and infants) to 
delivery visit. Longer-term follow-up of mothers and infants continues. 
 
Findings: 
Of 268 mothers randomized; all mothers and their infants were included in safety, and 250 mothers 
(125 dolutegravir, 125 efavirenz) and their infants in efficacy analyses by intention to treat analyses. 
The median duration of maternal therapy at delivery was 55 (IQR 33-77) days.  
 
Frequency of viral load<50 copies/mL at delivery visit was higher with dolutegravir (89/120, 74·2%) 
vs efavirenz (50/117, 42·7%); risk ratio (RR) and 95% CI, 1·64 (1·31-2·06). Although well-tolerated, 
more mothers on dolutegravir reported serious adverse events (30/137 vs 14/131; P = 0·013), 
particularly surrounding pregnancy and puerperium. There were no differences in births <37 weeks 
and <34 weeks gestation (16·4% and 3·3% respectively across both groups). Three stillbirths in the 
dolutegravir arm, and one in the efavirenz arm were considered unrelated to drug. Three infant HIV 




Dolutegravir achieves more rapid virological suppression compared to efavirenz, is well-tolerated 
when initiated in late pregnancy and may be preferred in this group of high-risk individuals 
 
Funding:  
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Delayed initiation of antiretroviral therapy until the third trimester of pregnancy is common in many 
settings where HIV is prevalent, and associated with increased mother-to-child transmission (MTCT) 
of HIV and infant mortality1-3. In the Uganda Demographic Health Survey, the first antenatal clinic 
appointment occurred at an average of 27·9 weeks1 and in South Africa, 11-19% of pregnant women 
presented at 28 weeks gestation or later 2,3.  
 
Whilst the causes of infant HIV transmissions are multifactorial, one important factor may be the 
inability of current first line efavirenz-based therapy to suppress HIV viral load by labour and delivery, 
a time when transmission risk is highest. The integrase inhibitor dolutegravir reduces HIV viral load 
rapidly to <50 copies per mL after a median of 28 days in non-pregnant adults compared with 84 
days for efavirenz4. Dolutegravir may consequently have special value for women presenting late in 
pregnancy, however safety and efficacy data are lacking.   
 
In order to evaluate if the rapid virological decline, tolerability and high HIV resistance barrier of 
dolutegravir containing regimens4 conferred additional benefits to HIV-positive women initiating 
treatment in late pregnancy, we undertook a randomized trial comparing dolutegravir with efavirenz-
based therapy in HIV-positive pregnant women initiating treatment in their third trimester of 







DolPHIN-2 (NCT03249181) is a randomised open-label trial in pregnant mothers initiating 
antiretroviral therapy in the third trimester of pregnancy. Eligible participants were enrolled in South 
Africa and Uganda. In Cape Town, participants were enrolled at Gugulethu Community Health 
Centre, following recruitment from 8 primary antenatal facilities in the surrounding area. In Kampala, 
participants were enrolled at the Infectious Diseases Institute, following recruitment at Kawempe 
Hospital (a tertiary obstetric referral unit) or 8 primary antenatal facilities throughout Kampala and 
Wakiso District. All participants were randomised 1:1 to receive efavirenz versus dolutegravir-based 
regimens. The primary efficacy outcome was HIV viral load <50 copies per mL at delivery, and the 
primary safety outcome was frequency of drug-related adverse events. Secondary outcomes 
included viral load <1000 copies per mL at delivery, occurrence of MTCT, and safety and tolerability 
of dolutegravir in mothers and breastfed infants.  
 
We report a pre-specified analysis of the primary efficacy outcome reached at the delivery visit (up 
to 14 days following birth), with accompanying safety data on mother-infant pairs to 6 weeks (+/- 2 
weeks) post-partum.  
 
Participants 
We enrolled participants if they met all the following inclusion criteria: women aged ≥18 years with 
untreated, but confirmed HIV infection; positive pregnancy test; estimated gestation ≥28 weeks; 
willing to provide informed consent. We excluded individuals with any of the following: i) received 
antiretroviral therapy in the preceding year or ever received integrase inhibitors, ii) documented 
virological failure of a non-nucleoside containing antiretroviral regimen, iii) previous efavirenz toxicity 
or other clinical history that would preclude randomisation, iv) estimated glomerular filtration rate <50 
mL/min, hemoglobin <8.0 g/dL, decompensated liver disease or alanine aminotransferase (ALT) >5 
times the upper limit of normal (ULN) or ALT >3xULN and bilirubin >2xULN (with >35% direct 
bilirubin) v) severe pre-eclampsia vi) medical, psychiatric or obstetric condition that might affect 
participation in the study, or vii) receiving any drugs known to significantly interact with efavirenz or 
dolutegravir within the preceding 2 weeks. From 1st June 2018 onwards, the protocol was amended 
to exclude pre-treatment HIV viral load <50 copies per mL. 
 
Ethics review committees in South Africa, Uganda and the UK approved the study. The Data and 
Safety Monitoring Board conducted a planned interim safety analysis after the first 125 mothers had 





Randomisation and Masking 
Since national policy required antiretroviral therapy to commence without delay in our study 
population, participants meeting eligibility criteria based on history and examination (prior to the 
availability of blood results) were enrolled with 1:1 block randomization (stratified by country, with 
concealment of allocation until assignment) to commence either dolutegravir or efavirenz on the 
same day. Any laboratory results which rendered the participant ineligible led to withdrawal at a 
confirmatory visit 7 days later.  
 
Procedures: 
Ultrasound examination was done at screening or within 2 weeks of enrolment across both sites. 
Gestational age at screening was a best estimate based on a combination of recall of last menstrual 
period, pubic symphysis-fundal height and fetal ultrasound (if undertaken at screening). The 
following tests were undertaken at screening: HIV-1 and -2 antibodies, CD4 count, full blood count, 
urea, creatinine and electrolytes, bilirubin, alanine aminotransferase and creatinine phosphokinase 
activity. HIV viral load and maternal safety bloods were also collected at 7 and 28 days following 
antiretroviral initiation, at 36 weeks gestation (if applicable), and at the delivery visit (0-14 days post-
partum). Study site deliveries were attended by study staff and for offsite deliveries, the study team 
arranged review of mothers and infants within 14 days. 
 
Antiretroviral therapy 
Mothers randomized to dolutegravir received Tivicay® 50mg/day together with generic tenofovir 
disoproxil fumarate (300mg) co-formulated with emtricitabine 200mg (South Africa) or lamivudine 
300mg (Uganda) once-daily. Mothers in the efavirenz arm received a generic single fixed 
combination pill of efavirenz 600mg with tenofovir plus either emtricitabine (South Africa) or 
lamivudine (Uganda). Each site had established protocols for supporting adherence, psychological 
counselling and health advice around pregnancy and breastfeeding. Use of traditional medications, 
supplements and other co-medications was checked at every study visit, and drug interactions 
managed as appropriate. In keeping with national guidelines in South Africa and Uganda, newborn 
infants were prescribed nevirapine for 6 weeks. 
 
Outcomes 
Safety evaluation and reporting in mothers and infants 
We categorised adverse events (AE) and serious adverse events (SAE) according to MedDRA5 with 
severity classified according to the DAIDS Grading Scale (version 2·1, July 2017). A Safety Endpoint 
Review Committee (blinded to allocation arm) assessed all SAEs, stillbirths, infant deaths and infant 
transmissions for relationship to study medication (using the Liverpool Adverse Drug Reaction 
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Causality Assessment Tool6) as well as likelihood of maternal Immune Reconstitution Inflammatory 
Syndrome (IRIS).  
 
Assessment of maternal and birth outcomes 
Case definitions for IRIS are heavily reliant on clinical judgement, given the relative lack of precision 
of symptoms and limited availability of diagnostic tests. For this study, we defined IRIS as any of the 
following developing within 12 weeks of treatment initiation, in the absence of an alternative 
diagnosis: i) fever and increased or new lymphadenopathy, or ii) pleural and pericardial effusions, 
ascites, abscess, cutaneous lesions and new or expanding central nervous lesions, iii) abnormal 
LFTs or hepatitis, or iv) atypical or exaggerated presentation of an opportunistic infection or tumour7-
9. Liver function abnormalities, preterm delivery, pre-eclampsia and neurological toxicity were also 
identified a priori as adverse events of special interest. 
 
Assessment of infant outcomes 
We conducted a delivery visit as soon as possible, and within 14 days of birth. For live births, we 
recorded the following infant outcomes at the delivery visit: mode of delivery, duration of rupture of 
membranes, any complications, neonatal length, weight and head circumference, Apgar score and 
evidence of intrauterine growth retardation. At the delivery visit (0-14 days post-partum) we used 
COBAS TaqMan for HIV-1 DNA tests at the research sites.  
 
We confirmed pre-term (<37 weeks gestation), and ‘premature’ (<34 weeks, classified as SAEs) 
births by Ballard Score10 if assessed within 7 days of delivery. Where any discrepancy arose, a 
pediatrician blinded to treatment arm assessed the infant and maternal dating evaluations within 48 
hours of birth. We evaluated congenital anomalies using the WHO protocol11. For all infant deaths, 
we sought consent for verbal autopsy in an attempt to elucidate the cause of death.  
 
We continue to follow-up mothers and infants to 72 weeks post-partum in order to assess the 
following secondary outcomes: maternal viral load response to 48 and 72 weeks  (% under 50 and 
1000 copies per mL), occurrence of infant HIV transmisisons at 48 and 72 weeks, dolutegravir 
exposure in maternal plasma, breast milk and infants and virological resistance.  
 
Statistical analysis 
Sample size calculations were based on clinical trials simulation (SAS v 9·3) using weighted 
probabilities (the weighted gestation-specific probabilities given different probabilities at different 
gestational ages) for achieving viral load <50 copies per mL for dolutegravir and efavirenz in 
treatment-naïve, non-pregnant adults4. Since the period of antiretroviral therapy prior to delivery 
could vary from a single dose to 12 weeks, we estimated statistical power from simulating five 
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different distributions of gestational age at starting treatment in the third trimester12. Allowing for 20% 
dropout rate, recruitment of 250 evaluable HIV-positive women would retain ≥99% power to detect 
a superiority absolute difference of 28–38% between arms across all scenarios at the 5% level of 
significance.  
 
Primary analyses were based on intention-to-treat. A generalised linear model (GLM) for the primary 
endpoint analysis included treatment as a study variable, baseline viral load (≥ or <100,000 copies 
per mL) and baseline CD4 (≥ or <200 cells per µL) as covariables, generating a risk ratio (RR; 95% 
CI) and risk difference (95% CI) between arms. Further covariate-adjusted GLM analysis of primary 
endpoint also incorporated age (< or ≥ median), country, and gestational age (< or ≥36 weeks) at 
baseline. Subgroup analysis was performed for each of the five pre-specified covariates. Sensitivity 
analysis of missing primary endpoint was also performed assuming (1) it did not achieve viral load 
<50 copies per mL; (2) it achieved viral load <50 copies per mL; and (3) it did not achieve 
suppression for dolutegravir group but achieved suppression for efavirenz group. 
 
For time-to-event analyses, we used the actual visit dates to calculate time of viral load suppression. 
Kaplan-Meier curves for each treatment group were compared by the log rank test and hazard ratio 
(95% CI), calculated using the Cox regression model with viral load and CD4-stratified covariables. 
Binary secondary outcomes were analyzed in a similar way as the primary endpoint analysis.   
 
Role of the funding source 
Neither ViiV Healthcare nor the study funder had any role in study design, data collection, data 
analysis, data interpretation, or writing of the report which remains the responsibility of the DolPHIN-
2 trial management group, accountable to the Trial Steering Committee. The corresponding author 







Between 23rd January-15th August 2018, we screened and randomized 268 pregnant mothers 
(Figure 1), with mothers and infants comprising the safety evaluation population followed to delivery 
visit and beyond. Following withdrawals due to laboratory results falling outside eligibility criteria 
(including a pre-treatment viral load <50 copies per mL) an ‘Intent to Treat’ (ITT) population of 250 
mothers (dolutegravir 125, efavirenz 125) was available for efficacy analyses with the last delivery 
visit on 21 December 2018. 
 
No significant differences were observed at baseline (Table 1) in median maternal age, gravidity, 
history of obstetric problems, median viral load or CD4 count. Use of herbal and traditional medicines 
was recorded in 34·8%, and vitamins or supplements in 37·6% of mothers. The median gestation at 
treatment initiation was 31 weeks with a median (IQR) time on treatment until delivery of 55 (33-77) 




The primary endpoint of viral load <50 copies per mL at delivery by ITT was met in 74·2% (89/120) 
mothers receiving dolutegravir compared with 42·7% (50/117) in the efavirenz arm (risk ratio 1·64, 
95%CI 1·31 - 2·06, P<0·0001; adjusted risk ratio 1·65, 95% CI 1·31 – 2·06, P <0·0001) – Table 2. 
The median time to achieve viral load<50 and <1000 copies per mL was 28 (95% CI: 28-34 ) and 7 
(95% CI: 7-20) days for dolutegravir, and 82 (95% CI: 55-97) and 23(95% CI: 21-27) days for 
efavirenz based on Kaplan-Meier estimates (Figure 2). In a covariate-adjusted analysis, the risk ratio 
was unaltered by maternal age, country, baseline viral load, baseline CD4 count or gestation at 
enrolment, with consistent between-treatment differences across these covariates and no significant 
interactions observed.  Sensitivity analysis (Table S1 p1) showed that results regarding the primary 
endpoint analyses are consistent and robust. The secondary endpoint of viral load<1000 copies per 
mL at delivery was also more likely achieved in women on dolutegravir vs efavirenz (93·3% vs 
82·1%) with an adjusted risk difference of 10·36% (0·26 – 20·47; P = 0·044) and an adjusted risk 
ratio of 1·10 (95%CI 0·99-1·23; P = 0·089) (Table 2, Figure 2).  
 
Three mother-to-child transmissions of HIV were detected, all in the dolutegravir arm and each 
confirmed by two to four separate HIV DNA-positive tests. The first infant tested HIV-positive at five 
days of age, after 35 days of maternal dolutegravir from 32 weeks of gestation. The second infant 
tested HIV DNA-positive at three days of age, after 32 days of maternal dolutegravir from 32 weeks 
of gestation while the third tested positive at 11 days, after 24 days of maternal dolutegravir from 30 
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weeks of gestation. The maternal viral load at delivery visit was <50 copies per mL in the first two 
cases (with baseline viral loads of 48,969 and 32,844 copies per mL), and in the third case, was 
31,354 copies per mL at baseline, and 200 copies per mL at delivery. We considered in-utero 
transmission likely given the early PCR-positivity of each infant, coupled with the low maternal viral 





Although antiretroviral therapy was well-tolerated across both arms, more mothers in the dolutegravir 
arm (30/137 vs 14/131; P = 0·013) reported any type of SAE.  This was driven by a higher overall 
frequency of ‘Pregnancy, Puerperium and Perinatal’ events in mothers receiving dolutegravir (Table 
3; supplementary table S2 p2-3), the majority of whom were judged to have prolonged pregnancy 
beyond term, with or without other conditions which led to Caesarean section being performed. 
Overall, there were 12 C-sections in the dolutegravir arm and 7 in the efavirenz arm (of which one 
was in the mother who had a stillbirth in the efavirenz arm). At the 28 day visit, we observed a modest 
increase in serum creatinine from baseline of 0.08mg/dL in the dolutegravir arm and of 0.02mg/dL 
for efavirenz; P<0·0001. Antepartum change in weight over the first 28 days of treatment did not 
differ between arms.  
 
Four stillbirths were reported (three in the dolutegravir arm; 2·2%). The first was a macerated stillbirth 
at 40w gestation, judged to be related to maternal syphilis. The second was at 36w gestation 
following uterine rupture and hemoperitoneum, with a history of maternal syphilis. The third fetus 
was a post-term pregnancy at 41w gestation, with evidence of fetal distress (efavirenz arm). The 
fourth was a macerated stillbirth at 41w gestation to a mother with a history of intermittent fevers 
(onset preceding antiretroviral therapy) and respiratory symptoms, presumptively treated for 
pulmonary tuberculosis; there was a history of traditional medicine use and treatment for malaria at 





A total of 242 evaluable live births (dolutegravir 123, efavirenz 119) were assessed, with a median 
gestation at delivery of 39 weeks for both arms, and no significant difference in pre-term and 
premature deliveries (Table 3), frequency of SAEs, or infant birthweights between arms.  Six infant 
deaths (dolutegravir-4, efavirenz-2) were reported (Table S4 p6). Two deaths were related to 
extreme prematurity (a 1-day old twin born at 28 weeks gestation in the efavirenz arm, and a 19-day 
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old infant born at 32 weeks gestation in the dolutegravir arm, whose mother suffered an antepartum 
hemorrhage). A further four deaths were related to respiratory distress or asphyxia: three in the 
dolutegravir arm (aged 2, 47 and 88 days, full term), one in the efavirenz arm (aged 14 days, born 
at 35 weeks gestation).  
 
Congenital disorders (Table S3 p4-5) also did not differ between arms, and comprised (dolutegravir 
vs efavirenz): umbilical hernias (37/124 (29·8%) vs 41/120 (34·2%)), birth marks (21/124 (16·9%) vs 
21/120 (17·5%)), skin dimples (dolutegravir-3), acrochordon (dolutegravir-2, efavirenz-3), 
heterochromia iridis (dolutegravir-1), laryngomalacia (dolutegravir-1), strabismus (dolutegravir-1, 
efavirenz-1), talipes (dolutegravir-1, efavirenz-2), cleft palate (efavirenz-1), polydactyly (efavirenz-






We found women on dolutegravir-based therapy were significantly more likely to achieve a VL of 
<50 copies per mL (or less likely to have a VL of ≥50 copies per mL) at delivery compared with those 
taking efavirenz regimens when initiated in the third trimester. These data address a critical 
knowledge gap around antepartum transmission of HIV in women initiating treatment late in 
pregnancy13-14 whereas other studies are assessing use of dolutegravir earlier in pregnancy.  
Undisclosed antiretroviral therapy was unlikely since we excluded mothers with VL <50 copies per 
mL at baseline. Smaller differences were observed in the proportion achieving HIV viral load <1000 
copies per mL than that of achieving HIV viral load <50 copies per mL, an alternative threshold for 
transmission risk15. In calculating the time from randomisation to the occurrence of achieving viral 
suppression, we used the actual visit dates at the scheduled visits of 7 and 28 days. Such an 
algorithm may bias the true time of viral load suppression, however since it was equally applied in 
both arms, any bias should be similar. Given that peri-partum HIV transmission is strongly correlated 
with the prevailing maternal viral load, dolutegravir based regimens may reduce HIV transmission 
around birth and potentially during breast feeding versus efavirenz-based regimens in our population 
of pregnant mothers. The three HIV-infected infants detected were considered likely in-utero 
infections, although peripartum transmission could not be excluded as we did not test infants within 
two days of birth. Longer follow-up to detect transmissions during breastfeeding is ongoing.   
 
We found both dolutegravir and efavirenz to be well-tolerated in mothers and infants. However, a 
higher proportion of mothers receiving dolutegravir developed SAEs.  This was driven by a higher 
overall frequency of ‘Pregnancy, Puerperium and Perinatal’ events in mothers receiving dolutegravir 
(supplementary table S1), the majority of whom were judged to have prolonged pregnancy beyond 
term. The significance of this finding is unclear, since estimation of gestational age in late pregnancy 
is not always accurate. It is important to examine whether our findings are replicated in other studies 
examining dolutegravir in pregnancy (e.g. VESTED; NCT03048422 and the Antiviral Pregnancy 
Registry). The incidence of serious adverse events and treatment-related toxicities overall was 
comparable to previous large randomised trials in non-pregnant adults in sub-Saharan Africa7,18,19.  
 
The infant deaths, stillbirths and infant transmissions observed attest to the poor outcomes 
previously reported in this group of mothers3. Detailed examination revealed that antiretroviral 
therapy or IRIS was considered unlikely to play a significant role in any of these cases. Of the four 
stillbirths, two were related to obstetric complications and two to severe maternal infection. The six 
infant deaths were related to conditions prevalent in Uganda and S Africa where neonatal mortality 
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rates are four to nine times those of Western Europe20,21. We did not observe any increased risk of 
birth defects, although treatment was only initiated after organogenesis was completed.  
 
Our sample size was not sufficiently large to study differences in infant transmissions, although we 
were powered to detect virological superiority by delivery (the best validated proxy for vertical HIV 
transmission). Safety follow-up of mothers and babies was limited given the relatively short time 
between third trimester initiation and our primary endpoint at delivery, however continued follow-up 
of post-partum and infant outcomes continues to 72 weeks. The higher frequency of SAEs observed 
with dolutegravir should be confirmed in other studies and observational datasets which are planned 
and in progress.  
 
Policymakers weigh risk-benefit of new treatments before data in pregnancy are available22. A 
preliminary association with neural tube defects triggered precautionary measures globally, ranging 
widely in permissiveness for dolutegravir use in women23-25, increasing the burden of healthcare 
provision26, and delaying implementation of dolutegravir rollout. Population modelling suggests that 
net population health benefits accrue when transitioning to dolutegravir, including for women of child 
bearing potential27,28. This would hold true notwithstanding the differences in SAEs amongst mothers 
assigned to dolutegravir. The DolPHIN-2 results, taken together with the current evidence favoring 
dolutegravir use over efavirenz (especially in countries where HIV drug resistance is increasing29) 
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Panel: Research in context 
 
Evidence before this study 
Late initiation of antiretroviral therapy in the third trimester of pregnancy is associated with a 
seven-fold increased risk of infant HIV transmissions, and a doubling of infant mortality in the first 
year of life. The period of greatest risk for mother-to-child HIV transmission is during labour and 
delivery, and risks are highest for mothers who are not virologically suppressed at this time. Using 
a PubMed search (‘HIV’, ‘pregnancy’, ‘initiation’, ‘antiretroviral therapy’, ‘Africa’; 10th February 
2020) we confirmed that across sub-Saharan Africa, late presentation for antiretroviral therapy 
during pregnancy is not uncommon (up to 1 in 5 pregnancies from South Africa). Conventional 
(efavirenz-based) antiretroviral  regimens may simply have insufficient time to suppress maternal 
HIV viral load quickly enough in this scenario. Newer, dolutegravir-based regimens are associated 
with faster declines in HIV viral load in non-pregnant adults, reaching undetectable (<50 copies 
per mL) viral load after a median of 28 days in comparison with 84 days for efavirenz. However, 
the safety and efficacy of dolutegravir in pregnancy is unknown, and there is a general lack of 
randomised trial data informing selection of newer antiretroviral regimens for use in pregnant 
mothers. Moreover, recent data from a large birth registry in Botswana suggest peri-conception 
use of dolutegravir was associated with an excess risk of neural tube defects. This safety concern 
has led to precautionary alerts from WHO and regulatory agencies, and the restriction of use of 
dolutegravir in pregnancy or women of child-bearing potential. 
 
Added value of this study 
DolPHIN-2 randomised 268 pregnant mothers initiating antiretroviral therapy in third trimester to 
receive either efavirenz- or dolutegravir-based regimens. Dolutegravir was associated with 
superior rates of viral load reduction. Although both regimens were well-tolerated by mothers and 
infants, more mothers receiving dolutegravir developed serious adverse events (driven mainly by 
prolonged pregnancies). The significance of this finding is uncertain, and should be confirmed in 
other studies. 
 
Implications of all the available evidence 
Risk-benefit evaluation of drug use in pregnancy needs to be separately undertaken according to 
trimester of exposure, especially given risks may be higher in early pregnancy, whereas benefits 
may be greater for pregnant mothers starting treatment in late pregnancy. The large differences 
in rates of virological suppression between both regimens suggest that significant public health 
benefits could accrue if dolutegravir-based therapy is widely implemented. Our data support the 
recent revision to WHO guidelines recommending transition to dolutegravir in first line 
antiretroviral therapy for all adults, regardless of pregnancy or child-bearing potential.  
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